BIND Therapeutics
101 Binney Street
Cambridge
Massachusetts
02142
United States
Tel: 617-491-3400
Fax: 617-491-0351
Website: http://www.bindbio.com/
Email: info@bindbio.com
133 articles about BIND Therapeutics
-
Former BIND Therapeutics CEO Joins Agios as New CFO
8/17/2016
-
Pfizer Wins Bid; Buys BIND Therapeutics Bankruptcy Assets for $40 Million
7/27/2016
-
Bankrupt BIND Therapeutics Reveals Two More Bidders Join Pfizer's Stalking Horse Bid
7/26/2016
-
BIND Therapeutics Stock Soars After Accepting Pfizer’s ‘Stalking Horse’ Asset Bid
7/6/2016
-
BIND Therapeutics Loses Two Polaris-Affiliated Board Directors
6/17/2016
-
BIND Therapeutics's Bankruptcy Filing Worries Developers Of Nanoparticle Cancer Drugs
5/24/2016
-
BIND Therapeutics Provides Update On Chapter 11 Proceedings And Announces Agreement With Hercules Technology III, L.P.
5/19/2016
-
BIND Therapeutics Release: Data Published In Journal Of Controlled Release Demonstrate Flexibility Of ACCURINS To Encapsulate A Broad Range Of Physically And Chemically Diverse Payloads With High Encapsulation Efficiency And Tunable Release Kinetics
5/10/2016
-
BIND Therapeutics Reports First Quarter 2016 Financial Results And Provides Business Update
5/9/2016
-
BIND Therapeutics Announces Collaboration With Affilogic To Provide BIND With Access To Targeting Ligands That Are Key Modulators Of Anti-Tumor Immunity
5/5/2016
-
BIND Therapeutics To Report First Quarter 2016 Financial Results On May 9, 2016
5/4/2016
-
Cambridge's BIND Therapeutics Files for Chapter 11 and Reviews Strategic Alternatives
5/3/2016
-
Shift in R&D Strategy Forces BIND Therapeutics to Slash 38% of Workforce, Look for New Capital and Deals
4/7/2016
-
Peptidream Announces Research Collaboration With BIND Therapeutics
4/6/2016
-
BIND Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Announces Shift In Research And Discovery Strategy To Focus On Based On ACCURINS® Platform Developing Innovative Medicines
3/15/2016
-
BIND Therapeutics To Report Fourth Quarter And Year-End 2015 Financial Results On March 15, 2016
3/9/2016
-
BIND Therapeutics And Synergy Pharma Announce Collaboration To Develop ACCURINS® With Proprietary Uroguanylin Analogs For Targeting Gastrointestinal Receptors On Tumors
2/16/2016
-
BIND Therapeutics Release: AZD2811 ACCURINS Data Published In Science Translational Medicine Highlight One Of The First Applications Of Nanomedicine To Molecularly Targeted Cancer Therapies
2/11/2016
-
BIND Therapeutics Provides Enrollment Update For Phase II Insite 1 And Insite 2 Trials With BIND-014
1/27/2016
-
BIND Therapeutics Complete Data On Clinical Activity Of BIND-014 In Patients With Metastatic Castration-Resistant Prostate Cancer (Mcrpc) At The 2016 Genitourinary Cancers Symposium
1/7/2016